{
  "source": "PA-Notification-Xuriden.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1192-10\nProgram Prior Authorization/Notification\nMedications Xuriden® (uridine triacetate)\nP&T Approval Date 6/2016, 6/2017, 6/2018, 6/2019, 6/2020, 6/2021, 6/2022, 6/2023,\n6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nXuriden® (uridine triacetate) is a pyrimidine analog for uridine replacement indicated in adult\nand pediatric patients for the treatment of hereditary orotic aciduria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Xuriden will be approved based on the following criterion:\na. Diagnosis of hereditary orotic aciduria\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Xuriden will be approved based on the following criterion:\na. Documentation of positive clinical response to Xuriden therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limitations may be in place\n4. References:\n1. Xuriden [package insert]. West Conshohocken, PA: BTG International Inc.; August 2023.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Xuriden® (uridine triacetate)\nChange Control\n6/2016 New program.\n6/2017 Annual review with no changes to criteria. Updated reference.\n6/2018 Annual review with no changes to criteria.\n6/2019 Annual review with no changes to criteria.\n6/2020 Annual review with no changes to criteria.\n6/2021 Annual review with no changes to criteria.\n6/2022 Annual review. Changed reauthorization to 12 mon",
    "9 Annual review with no changes to criteria.\n6/2020 Annual review with no changes to criteria.\n6/2021 Annual review with no changes to criteria.\n6/2022 Annual review. Changed reauthorization to 12 months to align with\nreauthorization period for other pharmacy programs. Updated\nbackground and reference.\n6/2023 Annual review with no change to criteria. Updated reference formatting\nand added state mandate footnote.\n6/2024 Annual review with no change to criteria. Updated reference.\n6/2025 Annual review with no changes to criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}